While the reduction in price target from $250 to $225 by Chardan Capital could be seen as a negative signal, the maintenance of a Buy rating suggests continued confidence in Alnylam Pharmaceuticals' long-term prospects. This mixed signal is likely to have a neutral short-term impact on ALNY's stock price, as the market balances the lowered price target with the reaffirmed positive outlook.